EBITDA: Income before interest, taxes, depreciation and amortization.
Lyell Immunopharma, Inc. (LYEL) had EBITDA of $-353.81M for the most recently reported fiscal year, ending 2024-12-31.
| Income Statement Financials | |
$0.06M |
|
$-342.99M |
|
-- |
|
$0.06M |
|
$358.82M |
|
$-358.75M |
|
$15.76M |
|
$-342.99M |
|
$-329.99M |
|
$-342.99M |
|
$-342.99M |
|
$-342.99M |
|
$-329.99M |
|
$-358.75M |
|
|
EBITDA |
$-353.81M |
261.48M |
|
261.48M |
|
$-1.31 |
|
$-1.31 |
|
| Balance Sheet Financials | |
$379.59M |
|
$48.20M |
|
$111.27M |
|
$490.86M |
|
$53.79M |
|
-- |
|
$54.25M |
|
$108.03M |
|
$382.82M |
|
$382.82M |
|
$382.82M |
|
294.88M |
|
| Cash Flow Statement Financials | |
$-162.39M |
|
$122.42M |
|
$1.33M |
|
$145.93M |
|
$107.29M |
|
$-38.64M |
|
$33.14M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
7.06 |
|
-- |
|
-- |
|
-- |
|
-- |
|
100.00% |
|
-588122.90% |
|
-588122.90% |
|
-580008.10% |
|
-562285.30% |
|
-562285.20% |
|
$-194.20M |
|
-- |
|
-- |
|
-- |
|
0.00 |
|
-- |
|
-- |
|
-- |
|
-89.60% |
|
-89.60% |
|
-69.88% |
|
-89.60% |
|
$1.30 |
|
$-0.74 |
|
$-0.62 |
|